Skip to Content

Evista (raloxifene) Disease Interactions

There are 5 disease interactions with Evista (raloxifene):


Raloxifene (Includes Evista) ↔ Thromboembolism

Severe Potential Hazard, High plausibility

Applies to: Thrombotic/Thromboembolic Disorder, History - Thrombotic/Thromboembolic Disorder, Congestive Heart Failure, Pulmonary Embolism

The use of raloxifene is contraindicated in patients with active or past history of venous thromboembolic events, including deep vein thrombosis, pulmonary embolism, and retinal vein thrombosis. In clinical trials, women treated with raloxifene had an increased risk of venous thromboembolism. A less serious event, superficial thrombophlebitis, also has been reported more frequently with raloxifene. The greatest risk for deep vein thrombosis and pulmonary embolism occurs during the first four months of treatment. Therapy with raloxifene should be considered cautiously in women at risk for thromboembolic disease for other reasons, such as congestive heart failure, superficial thrombophlebitis, and active malignancy.


  1. "Product Information. Evista (raloxifene)." Lilly, Eli and Company, Indianapolis, IN.

Raloxifene (Includes Evista) ↔ Heart Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Heart Disease

In studies of postmenopausal women with documented coronary heart disease or at increased risk for coronary events, an increased risk of death due to stroke was observed after treatment with raloxifene. The risk-benefit balance should be considered in women at risk for stroke, such as prior stroke or transient ischemic attack (TIA), atrial fibrillation, hypertension, or cigarette smoking.


Raloxifene (Includes Evista) ↔ Hypertriglyceridemia

Moderate Potential Hazard, Moderate plausibility

Applies to: Hyperlipidemia

In studies of women with a history of marked hypertriglyceridemia (>5.6 mmol/L or >500 mg/dL) in response to treatment with oral estrogen or estrogen plus progestin may develop increased levels of triglycerides when treated with raloxifene. Women with this medical history should have serum triglycerides monitored when taking raloxifene.


Raloxifene (Includes Evista) ↔ Liver Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Liver Disease

Raloxifene undergoes extensive first-pass metabolism in the liver. Following administration of a single oral dose in Child-Pugh Class A patients with cirrhosis and total serum bilirubin ranging from 0.6 to 2.0 mg/dL, plasma raloxifene concentrations were 2.5 times higher than in controls. Therapy with raloxifene should be administered cautiously in patients with hepatic insufficiency, since safety and efficacy have not been evaluated. Although raloxifene is generally well tolerated, even at dosages higher than currently recommended, patients with liver disease should be monitored for occurrence of undue adverse effects during raloxifene therapy.


  1. "Product Information. Evista (raloxifene)." Lilly, Eli and Company, Indianapolis, IN.

Raloxifene (Includes Evista) ↔ Renal Impairment

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction

Raloxifene should be used with caution in patients with moderate or severe renal impairment.

Evista (raloxifene) drug Interactions

There are 63 drug interactions with Evista (raloxifene)

Evista (raloxifene) alcohol/food Interactions

There is 1 alcohol/food interaction with Evista (raloxifene)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.